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Abstract
The omega-3 fatty acid eicosapentaenoic acid (EPA) has multiple actions potentially conferring cardiovascular
benefit, including lowering serum triglyceride (TG) and non-high-density lipoprotein cholesterol (non-HDL-C) levels
and potentially reducing key steps in atherogenesis. Dietary supplements are a common source of omega-3 fatty
acids in the US, but virtually all contain docosahexaenoic acid (DHA) in addition to EPA, and lipid effects differ
between DHA and EPA. Contrary to popular belief, no over-the-counter omega-3 products are available in the US,
only prescription products and dietary supplements. Among the US prescription omega-3 products, only one
contains EPA exclusively (Vascepa); another closely related prescription omega-3 product also contains highly
purified EPA, but is approved only in Japan and is provided in different capsule sizes. These high-purity EPA
products do not raise low-density lipoprotein cholesterol (LDL-C) levels, even in patients with TG levels >500 mg/
dL, in contrast to the increase in LDL-C levels with prescription omega-3 products that also contain DHA. The
Japanese prescription EPA product was shown to significantly reduce major coronary events in hypercholesterolemic
patients when added to statin therapy in the Japan EPA Lipid Intervention Study (JELIS). The effects of Vascepa on
cardiovascular outcomes are being investigated in statin-treated patients with high TG levels in the Reduction of
Cardiovascular Events With EPA-Intervention Trial (REDUCE-IT).
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Background
Eicosapentaenoic acid (EPA) is an omega-3 polyunsatur-
ated fatty acid with a broad range of potentially beneficial
cardiovascular effects [1, 2]. Chemically, EPA is designated
as 20:5, n-3, indicating that it is a 20-carbon fatty acid
containing 5 double bonds, with the first double bond lo-
cated at the third carbon atom from the distal end of the
fatty acid tail [3]. This unique chemical structure has im-
portant biological consequences. By replacing the omega-
6 fatty acid arachidonic acid (AA; 20:4, n-6) in membrane
phospholipids, EPA can alter the physical properties of
cellular membranes. Further, its metabolism can give rise
to anti-inflammatory and anti-thrombotic lipid mediators,
in contrast to pro-inflammatory pro-thrombotic factors
which tend to be produced from AA [1, 3–5]. Available
highly purified EPA prescription products consist of the
ethyl ester of EPA because this form allows preparation of
omega-3 fatty acids at far greater purity than those avail-
able by other purification methods [6].
In clinical studies, EPA has been shown to lower trigly-
ceride (TG) and non-high-density lipoprotein cholesterol
(non-HDL-C) levels, as well as other key lipid/lipoprotein
parameters [7, 8]. Unlike products containing the omega-
3 fatty acid docosahexaenoic acid (DHA), however, EPA
does not raise low-density lipoprotein cholesterol (LDL-C)
levels [7–9]. Additionally, EPA has other non-lipid and
non-lipoprotein effects that appear to beneficially re-
duce multiple steps in atherogenesis [10], including
protecting against oxidative damage [5, 11–13], im-
proving vascular and endothelial function [14–16],
inhibiting monocyte movement into early lesions and
subsequent conversion to macrophages and foam cells
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[17–19], modulating inflammation [20, 21], supporting
anti-oxidant and anti-inflammatory functions of high-
density lipoprotein (HDL) [22], promoting HDL-mediated
cholesterol efflux from macrophages [22], reducing
atherosclerotic plaque formation, progression, and
vulnerability to rupture [18, 23–27], and decreasing
platelet-mediated thrombus formation [28, 29]. EPA also
may reduce blood pressure, likely attributable to improve-
ment of endothelial function [30]. Importantly, many of
these effects have been observed with EPA alone or are
additive to those of statins. In contrast, EPA’s effects on ar-
rhythmias are complex and equivocal [30].
Lipid guidelines and recommendations vary regarding
the suggested use of omega-3 fatty acids in general and,
when mentioned, EPA in particular. For example, the
National Lipid Association (NLA) recommends omega-3
fatty acids as a first-line option for patients with very high
TG levels (≥500 mg/dL) and as an add-on option to statin
therapy for those with high TG levels (200–499 mg/dL) in
order to achieve specific lipid goals, but notes that omega-
3 fatty acid drugs may raise LDL-C levels if they contain
DHA [31]. The American College of Cardiology/American
Heart Association (ACC/AHA) cholesterol treatment
guidelines note in passing the efficacy of omega-3 fatty
acids in reducing TG levels in patients with severe
hypertriglyceridemia [32] but focus on diet and lifestyle
measures, and contain very little about prescription
omega-3 agents in particular, or on TG-lowering medica-
tions in general. The Japan Atherosclerosis Society
(JAS) indicates that the addition of EPA to a statin
can be useful for treating high-risk patients with
LDL-C levels ≥140 mg/dL [33].
Most prescription omega-3 products approved in the
US have both EPA and DHA, as do virtually all mar-
keted dietary supplements. Only two prescription formu-
lations of highly purified EPA (without DHA) are
currently approved in the world: Epadel® in Japan (ethyl
icosapentate; Mochida Pharmaceuticals Co, Ltd, Tokyo,
Japan) and Vascepa® in the US (icosapent ethyl; Amarin
Pharma Inc., Bedminster, NJ, USA). This review exam-
ines key safety and efficacy considerations of these two
highly purified prescription EPA products.
Prescription EPA products
Epadel was approved in Japan more than 2 decades ago,
and is indicated for the treatment of hyperlipidemia as
well as improvement of ulcer, pain, and cold feeling associ-
ated with arteriosclerosis obliterans [34]. Vascepa was ap-
proved in the US in 2012, and is indicated as an adjunct to
diet to reduce TG levels in adults with severe hypertriglyc-
eridemia (≥500 mg/dL) [35]. Both are composed of highly
purified EPA ethyl ester (Table 1) [7, 34–36]; however,
their purification processes differ slightly and their capsule
size and dosing recommendations differ. Epadel (approved
only in Japan) is usually administered at a dose of 1.8 g/
day (0.6 g tid after food) and can be increased to 2.7 g/day
if TG levels remain abnormal [34]. Epadel is available as
300-mg, 600-mg, and 900-mg capsules to be taken two or
three times daily after meals to achieve the desired daily
dose [34]. Vascepa (approved only in the US) is manufac-
tured as 500-mg and 1000-mg capsules and is approved at
a dose of 4 g/day, to be given as two 1000-mg capsules, or
four 500-mg capsules, twice daily with food [35].
Table 1 Prescription EPA Products [34, 35]
Epadel Vascepa
Year approved 1988 2012
Country Japan USA
Generic name Ethyl icosapentate; icosapent Icosapent ethyl
Structure
Molecular formula C22H34O2 C22H34O2
Molecular weight 330.50 330.51
Indications Hyperlipidemia; improvement of ulcer, pain
and cold feeling associated with arteriosclerosis
obliterans
Adjunct to diet to reduce TG levels in adults
with severe (≥500 mg/dL) hypertriglyceridemia
Formulation 300-mg, 600-mg, or 900-mg capsules 500-mg or 1000-mg capsules
Dosage and administration 1.8 g/daya (twice daily after meals) 4 g/day (twice daily with food)
aRecommended dosage for treatment of hyperlipidemia; dose may be increased to 1 capsule three times per day if TG levels are abnormal. EPA eicosapentaenoic
acid, TG, triglyceride
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Safety and tolerability of prescription EPA
products
In JELIS, adverse events (AEs) that were more common in
the Epadel group than the control group were, respect-
ively, gastrointestinal disturbance (nausea, diarrhea, or
epigastric discomfort; 3.8 vs 1.7%; P <0.0001), skin abnor-
mality (eruption, itching, exanthema, or eczema; 1.7 vs
0.7%; P <0.0001), hemorrhage (cerebral, fundal, epistaxis,
and subcutaneous; 1.1 vs 0.6%; P = 0.0006), and increased
glutamic oxaloacetic transaminase (0.6 vs 0.4%; P = 0.03)
[36]. Beyond JELIS, the safety of Epadel has been followed
for more than 15 years in spontaneous reporting in post-
marketing regulatory safety surveillance, as well as in sev-
eral randomized clinical trials in Japan. It has been shown
to have very good safety and tolerability, with AEs re-
ported in 665 of 15,081 patients (4.4%) [34]. The most
common AEs were nausea (0.44%) and abdominal dis-
comfort (0.32%). Vascepa has also been shown to be safe
and well tolerated, with a safety profile similar to placebo
in patients with hypertriglyceridemia in the Multi-center,
Placebo-controlled, Randomized, Double-blind, 12-week
Study with an Open-label Extension (MARINE) and
ANCHOR studies [7, 8]. In a pooled analysis of Vascepa
clinical trials, arthralgia was the only AE that oc-
curred in >2% of patients and with an incidence
greater than placebo (14/622 [2.3%] Vascepa patients
vs 3/309 [1.0%] placebo patients) [35]. In addition, no
drug-drug interactions between Vascepa and atorva-
statin, warfarin, rosiglitazone, or omeprazole were ob-
served in pharmacokinetic studies [37–40].
Omega-3 fatty acids tend to reduce platelet activity,
which might contribute to their potential cardiovascular
benefits [41], but which might also lead to excess bleed-
ing. Some studies of omega-3 fatty acids have docu-
mented a prolongation of bleeding time, although not
exceeding normal limits [34, 35]. Further, an aggregate
endpoint of various types of hemorrhage was increased
slightly with Epadel in the Japan EPA Lipid Intervention
Study (JELIS) [36]. It is recommended that patients re-
ceiving treatment with Vascepa or Epadel should be
monitored periodically on a clinical basis only (without
any recommended testing) when either of these drugs is
added to medications that affect coagulation [34, 35].
Such monitoring does not differ, however, from that rec-
ommended for such patients not taking EPA. Import-
antly, omega-3 fatty acids do not appear to increase the
risk of clinically significant bleeding when used alone or
in combination with antiplatelet or antithrombotic medi-
cations [41–43].
Efficacy of prescription EPA products
Epadel
In clinical studies of Japanese patients with elevated TG
levels, Epadel reduced serum TG levels by 14 to 20%
and total cholesterol levels by 3 to 6%, with stable effects
from 24 to 52 weeks [34]. The magnitude of the TG ef-
fects was related to baseline TG values in that TG de-
creases of −23, −103, and −172 mg/dL were noted with
baseline levels of 150–299 mg/dL, 300–599 mg/dL, and
≥600 mg/dL, respectively. Similarly, decreases in serum
cholesterol were proportional to baseline levels, as de-
creases of −6, −18, and −28 mg/dL occurred in patients
with baseline levels of 220–259 mg/dL, 260–299 mg/dL,
and ≥300 mg/dL, respectively.
The effect of Epadel on cardiovascular outcomes was
investigated in JELIS, which was a prospective, random-
ized, open-label, blinded endpoint evaluation (PROBE)
trial that enrolled 18,645 hypercholesterolemic Japanese
patients (baseline total cholesterol ≥250 mg/dL and
LDL-C ≥170 mg/dL) with or without coronary artery
disease (CAD) [36, 44]. Patients received pravastatin
10 mg or simvastatin 5 mg daily as first-line treatment,
which was up-titrated as needed to achieve goal LDL-C
levels, as recommended by Japanese guidelines [36, 44].
Patients were then randomized to receive Epadel (1.8 g/
day as 0.6 g three times daily) or no additional treatment
(control group). The primary endpoint was any major
coronary event, consisting of sudden cardiac death, myo-
cardial infarction (MI), unstable angina pectoris, angio-
plasty, stenting, or coronary artery bypass grafting [36].
Among JELIS patients, 14,981 had no CAD at baseline
(primary prevention cohort) and 3664 had documented
CAD (secondary prevention cohort) [36]. At baseline,
the mean total cholesterol and LDL-C levels were 274
and 181 mg/dL, respectively, and the median TG level
was 153 mg/dL [36]. Upon study entry, patients received
statin therapy up-titrated to achieve cholesterol goals
per Japanese guidelines, consisting of pravastatin or sim-
vastatin at mean daily doses of 10.0 and 5.6 mg, respect-
ively. In contrast to the studies noted above, Epadel had
only modest TG-lowering effects (9% in the EPA group
vs 4% in the control group, a difference of approximately
5%), without changes in other lipid levels. After a mean
follow-up of 4.6 years, Epadel significantly reduced risk
of major coronary events by 19% compared with control
(hazard ratio [HR], 0.81; 95% confidence interval [CI],
0.69–0.95; P = 0.011) [36]. A very important but largely
unrecognized fact about JELIS is that it was the first ran-
domized clinical trial to show additional cardiovascular
benefit of any medication added to a statin. A statisti-
cally significant risk reduction for major coronary events
with Epadel was also seen in the secondary prevention
cohort alone (HR, 0.81; 95% CI, 0.657–0.998; P = 0.048),
and a similar trend, albeit not statistically significant,
was seen in the primary prevention cohort alone (HR,
0.82; 95% CI, 0.63–1.06; P = 0.132). Of the secondary
endpoints evaluated, Epadel significantly reduced risk of
unstable angina in the entire study population (HR, 0.76;
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P = 0.014) and in the secondary prevention cohort (HR,
0.72; P = 0.019) [36]. Although the largest numbers of
patients with primary endpoint events had “soft” end-
points of unstable angina (n = 340) or revascularization
(n = 413), which may have resulted from bias due to the
open-label nature of the trial, it is important to note that
primary prevention for two composites of “hard” end-
points, coronary death or MI, and fatal or nonfatal MI,
were decreased by 22 and 23%, respectively, comparable
to that of the primary composite endpoint of 19% [36].
This strongly suggests that the positive finding of cardio-
vascular disease event reduction in JELIS was not an
artifact of the open-label trial design.
Substudies of JELIS explored the relationship between
patient types and cardiovascular disease benefit from
Epadel therapy (Table 2). In the primary prevention co-
hort, 957 patients had TG levels ≥150 mg/dL and high-
density lipoprotein cholesterol (HDL-C) levels <40 mg/dL
at baseline. These patients exhibited an elevated risk of
developing CAD compared with those without these ab-
normalities, and Epadel greatly reduced the risk of major
coronary events in this high-risk subgroup by 53% com-
pared with the control group (HR, 0.47; 95% CI, 0.23–
0.98; P = 0.043) [45]. Surprisingly, the lipid effects of EPA
were also very modest in this subgroup (as in the overall
study population) despite the higher baseline TG level
(median 272 mg/dL), with TG level decreases of 23 versus
18% in the Epadel and control groups, respectively. In a
somewhat related finding, in a cohort of 4565 JELIS
patients with impaired glucose metabolism (defined as
fasting blood glucose ≥110 mg/dL, diabetes, or use of anti-
diabetic drugs), Epadel significantly reduced the risk of
major coronary events by 22% compared with control
treatment (HR, 0.78; 95% CI, 0.60–0.998; P = 0.048) [46].
Epadel was also similarly effective in reducing the risk of
major coronary events in other high-risk subgroups, in-
cluding patients with prior peripheral artery disease (56%;
HR, 0.44; 95% CI, 0.19–0.97) [47], not achieving LDL-C
and HDL-C goals (38%; HR, 0.62; 95% CI, 0.43–0.88) [48],
and with either prior MI (27%; HR, 0.73; 95% CI, 0.54–
0.98) or prior coronary intervention (35%; HR, 0.65; 95%
CI, 0.48–0.89) [49]. Epadel also decreased recurrent stroke
by 20% (HR, 0.80; 95% CI, 0.64–0.997; P = 0.047) in the
secondary prevention subgroup [50]. In an analysis of pa-
tient adherence in JELIS, EPA conferred substantial risk
reduction in sudden cardiac death and fatal/non-fatal MI
compared with statin alone (HR, 0.55; 95% CI, 0.34–0.88;
P = 0.014) in the secondary prevention population of pa-
tients with good adherence to EPA plus statin therapy
[51]. As expected, analyses of fatty acids in patients from
JELIS found that intervention with EPA led to an increase
in both plasma EPA concentration and the EPA/AA ratio.
Importantly, the risk of major coronary events (primary
study endpoint) was reduced proportionally to the in-
creases in plasma EPA concentration and EPA/AA ratio
[52].
Two large ongoing clinical trials are evaluating EPA-
only therapy in an effort to confirm the results of JELIS.
One trial is examining the effects of EPA added to a statin
on the incidence of cardiovascular events in patients with
CAD. The EPA being used is Epadel and the trial is titled
the Randomized Trial for Evaluation in Secondary Preven-
tion Efficacy of Combination Therapy-Statin and Eicosa-
pentaenoic Acid (RESPECT-EPA) [53]. The primary
endpoints include a composite of CAD including sudden
cardiac death, MI, revascularization, and hospitalization
Table 2 Effect of Epadel on Risk of Major Coronary Eventsa in JELIS and JELIS Substudies
Analysis Group Cohort N HR (95% CI) P Value Reference
JELIS All patients 18,645 0.81 (0.69–0.95) 0.011 Yokoyama, 2007 [36]
Impaired glucose metabolismb All patients 4565 0.78 (0.60–0.998) 0.048 Oikawa, 2009 [46]
Peripheral artery disease All patients 223 0.44 (0.19–0.97) 0.041 Ishikawa, 2010 [47]
JELIS 1° prevention 14,981 0.82 (0.63–1.06) 0.132 Yokoyama, 2007 [36]
TG ≥150 mg/dL and/or HDL-C <40 mg/dL 1° prevention 957 0.47 (0.23–0.98) 0.043 Saito, 2008 [45]
Patients not achieving LDL-C and non-HDL-C goalsc 1° prevention 6592 0.62 (0.43–0.88) 0.007 Sasaki, 2012 [48]
JELIS 2° prevention 3664 0.81 (0.657–0.998) 0.048 Yokoyama, 2007 [36]
Prior myocardial infarction 2° prevention 1050 0.73 (0.54–0.98) 0.033 Matsuzaki, 2009 [49]
Prior coronary intervention 2° prevention 895 0.65 (0.48–0.89) 0.007 Matsuzaki, 2009 [49]
CI confidence interval, HDL-C high-density lipoprotein cholesterol, HR hazard ratio, JELIS Japan EPA Lipid Intervention Study, LDL-C low-density lipoprotein choles-
terol, non-HDL-C non-high-density lipoprotein cholesterol, TG triglyceride
aThe primary endpoint, major coronary events, consisted of sudden cardiac death, myocardial infarction, unstable angina pectoris, angioplasty, stenting, or
coronary artery bypass grafting [36]
bDefined as fasting plasma glucose ≥110 mg/dL at study registration or after 6 months, physician-diagnosed diabetes mellitus, or use of antidiabetic drugs within
first year of study [46]
cLDL-C goal as recommended in 2007 Japanese Atherosclerosis Society guidelines and a non-HDL-C goal of 30 mg/dL higher than the LDL-C goal as recom-
mended in Adult Treatment Panel III guidelines [48]
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for unstable angina and a composite of cerebrovascular
disorders including fatal and non-fatal stroke. The other
trial is testing Vascepa and is detailed in the next section.
Recently, the Combination Therapy of Eicosapentaenoic
Acid and Pitavastatin for Coronary Plaque Regression
Evaluated by Integrated Backscatter Intravascular Ultra-
sonography (CHERRY) study investigated the effects of
Epadel 1.8 g/day with pitavastatin 4 mg/day versus pita-
vastatin alone on the progression of coronary plaque via
integrated backscatter intravascular ultrasound in approxi-
mately 200 patients [54, 55]. After 6 – 8 months, total
plaque volume and volume of the lipid-rich portion of the
plaques were significantly decreased in the EPA arm after
adjustment for confounding factors. Specifically, the per-
centage of patients with plaque regression was signifi-
cantly higher with EPA versus without EPA (50 vs 24%,
respectively; P <0.001) [55]. The change in the EPA/AA
ratio, which was, of course, significantly increased in the
group receiving EPA, correlated significantly and inversely
with the change in plaque volume (r = −0.332; P <0.001).
These improvements in coronary atherosclerosis corrob-
orate the decrease in cardiovascular events in JELIS and
suggest that EPA may reduce the residual cardiovascular
risk in patients with prior CHD who are already on
moderate-intensity statin treatment.
Vascepa
The efficacy of Vascepa in modulating lipid levels was
demonstrated in 2 randomized, double-blind, placebo-
controlled, multicenter phase 3 studies known as MAR-
INE and ANCHOR [7, 8]. In both studies, patients entered
a 4–6-week stabilization period during which they were
provided dietary instructions and discontinued any
other TG-lowering therapy such as fibrates, niacin, or
omega-3 fatty acids. Treatment with stable doses of a
statin with or without ezetimibe was allowed in MAR-
INE and was required in ANCHOR. After the
stabilization period in MARINE, 229 patients with very
high TG levels (≥500 and ≤2000 mg/dL) were random-
ized to treatment with Vascepa 4 g/day, Vascepa 2 g/
day, or placebo for 12 weeks [7]. Both doses of Vascepa
significantly reduced TG levels. Compared with pla-
cebo, the median change in TG levels from baseline
was −33.1% (P <0.0001) with the 4 g/day dose and
−19.7% (P = 0.0051) with the 2 g/day dose. Both doses
of Vascepa also significantly reduced non-HDL-C and
total cholesterol levels compared with placebo, but did
not significantly affect LDL-C or HDL-C levels (Fig. 1).
In ANCHOR, 702 patients with high TG levels (≥200
and <500 mg/dL) and optimal LDL-C levels (≥40 and
<100 mg/dL) on statin therapy were randomized to
Fig. 1 Effect of Vascepa on lipid levels in patients with very high TG levels (≥500 and ≤2000 mg/dL) in the MARINE study. Shown are the median
changes from baseline to week 12 in the intent-to-treat population [7]. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; MARINE, Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week Study with an Open-label Extension; Non-HDL-C, non-high-
density lipoprotein cholesterol; TG, triglyceride; Total C, total cholesterol
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treatment with Vascepa 4 g/day, Vascepa 2 g/day, or
placebo for 12 weeks [8]. Again, compared with pla-
cebo, both doses of Vascepa significantly reduced TG
levels, with a median change from baseline of −21.5%
for the 4 g/day dose (P <0.0001) and −10.1% for the
2 g/day dose (P = 0.0005). Compared with placebo, both
doses of Vascepa significantly reduced non-HDL-C and
total cholesterol levels, and the 4 g/day dose produced
small but statistically significant reductions in LDL-C
and HDL-C levels (Fig. 2).
Further laboratory testing in MARINE and ANCHOR
revealed that Vascepa has additional, and apparently
beneficial, effects. Vascepa 4 g/day significantly reduced
circulating markers of inflammation and oxidation, in-
cluding high-sensitivity C-reactive protein by −36% in
MARINE (P <0.01) and −22% in ANCHOR (P <0.001),
lipoprotein-associated phospholipase A2 by −14% in
MARINE (P <0.001) and −19% in ANCHOR (P <0.0001),
and oxidized low-density lipoprotein (LDL) by −13% in
ANCHOR (P <0.0001) compared with placebo [21].
Importantly, Vascepa 4 g/day did not worsen glycemic
control in the subset of ANCHOR patients with type
2 diabetes compared with placebo [56]. Interestingly,
the effects of Vascepa appeared numerically more
pronounced in patients with less-controlled diabetes
(hemoglobin A1c greater than the median value of
6.8%) than in those with better-controlled diabetes
[56]. As expected, treatment with Vascepa 4 g/day
and 2 g/day in MARINE and ANCHOR led to signifi-
cant increases in plasma EPA (see subsequent section
on plasma EPA levels) and corresponding decreases in the
AA/EPA ratio compared with placebo (P <0.0001 for all
comparisons) [57, 58].
Lipoprotein content and lipoprotein particle concentra-
tion and size are additional factors that may influence
atherogenicity. Levels of apolipoprotein B (apoB) were
significantly reduced with Vascepa 4 g/day in MARINE
(P = 0.0019) and ANCHOR (P <0.0001) [7, 8]. In MARINE,
nuclear magnetic resonance analyses (LipoScience, Inc.
LipoProfile) showed that Vascepa 4 g/day significantly
reduced particle concentrations of large very-low-
density lipoprotein cholesterol (VLDL) (P = 0.0211),
total LDL (P = 0.0006), small LDL (P <0.0001), and total
HDL (P = 0.0063), as well as VLDL particle size (P = 0.0017)
compared with placebo [59]. Similar results were observed
in ANCHOR, where Vascepa 4 g/day significantly reduced
particle concentrations of total VLDL (P = 0.0002),
LDL (P = 0.0017), and HDL (P <0.0001) and large
VLDL, small LDL, and large HDL (all P <0.0001), and
caused corresponding changes in lipoprotein particle sizes
[60]. The reduction in LDL particle concentration with
pure EPA is a novel finding among prescription omega-3
fatty acids, and is consistent with data showing that
Vascepa significantly lowers apoB [59, 60]. Vascepa
Fig. 2 Effect of Vascepa on lipid levels in patients with high TG levels (≥200 and <500 mg/dL) despite LDL-C control while on statin therapy in
the ANCHOR study. Shown are the median changes from baseline to week 12 in the intent-to-treat population [8]. HDL-C, high-density lipopro-
tein cholesterol; LDL-C, low-density lipoprotein cholesterol; Non-HDL-C, non-high-density lipoprotein cholesterol; TG, triglyceride; Total C,
total cholesterol
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also is reported to reduce remnant-like particle cholesterol
(RLP-C) levels in MARINE and ANCHOR [61] using an
immunoseparation assay [62–64]. Remnant lipoproteins
are partially catabolized TG-rich lipoproteins, are known
to be atherogenic in the relatively uncommon situation of
dysbetalipoproteinemia, and are thought to be a risk factor
for atherosclerotic cardiovascular disease in the general
population. Although some recent publications have pre-
sented calculated remnant cholesterol levels (obtained
from a basic lipid panel by subtracting calculated LDL-C
from non-HDL-C) as a readily obtainable surrogate for
measured RLP-C levels [65], it should be noted that such
a calculation is the same as simply dividing the measured
plasma or serum TG level by 5 and thus does not contrib-
ute uniquely to our understanding of remnant levels. Fi-
nally, Vascepa 4 g/day significantly reduced apolipoprotein
C-III (apoC-III) levels compared with placebo in MARINE
and ANCHOR (both P <0.0001) [66]. ApoC-III impairs
TG lipolysis and hepatic uptake of TG-rich lipoproteins, is
strongly and positively related to levels of remnant lipo-
proteins, and appears to promote atherogenesis by these
and other mechanisms [67].
To investigate potential direct antioxidant mechanisms
by which Vascepa may lower circulating levels of apoB-
containing atherogenic lipoprotein particles, an in vitro
assay assessed the antioxidant effects of EPA on small
dense LDL, LDL, and VLDL isolated from human
plasma [13]. EPA was found to inhibit the oxidation of
small dense LDL and LDL in a dose-dependent manner
and also inhibited VLDL oxidation with higher potency
than the other lipoprotein species [13]. Notably, this in-
hibition of particle oxidation was enhanced when EPA
was combined with the active metabolite of atorvastatin,
while DHA caused less inhibition of oxidation of the
apoB-containing particles than did EPA [13].
A large cardiovascular outcome trial of Vascepa is now
well underway. It is examining the effects of EPA on car-
diovascular outcomes in high-risk patients with persist-
ent hypertriglyceridemia despite statin therapy and
either established or high cardiovascular disease risk.
The trial is titled the Reduction of Cardiovascular
Events With EPA–Intervention Trial (REDUCE-IT;
NCT01492361) [68]. Patients with a fasting TG level
≥150 mg/dL (or ≥200 mg/dL, depending on the phase of
trial recruitment) are being randomized to Vascepa 4 g/
day or placebo, and the primary efficacy endpoint is a
composite of cardiovascular death, MI, stroke, revascu-
larization, and hospitalization for unstable angina. The
study is anticipated to be completed in late 2017 with re-
sults available in 2018. It should be noted that Vascepa
is not approved by the US FDA to reduce the risk of cor-
onary heart disease; the effect of Vascepa on the risk of
cardiovascular mortality and morbidity has not been
determined.
Prescription EPA-only products versus other
omega-3 fatty acid products
Vascepa is the only highly purified EPA prescription prod-
uct approved in the US. Other products, including other
prescription omega-3 fatty acid formulations [69–71] and
dietary supplements [72, 73], contain substantial amounts
of DHA in addition to EPA. DHA (22:6, n-3) is structur-
ally and chemically distinct from EPA, and although DHA
can be derived metabolically from EPA, very little, if any,
of the reverse conversion (DHA to EPA) occurs in
vivo [3, 74]. Importantly, products containing DHA
have been shown to raise LDL-C levels, which may
attenuate its other lipid benefits [9, 70, 71, 75–77]. In con-
trast, products with EPA but lacking DHA do not raise
LDL-C levels (compared with placebo or control), as
noted with Vascepa in MARINE and ANCHOR and with
Epadel in JELIS in certain patient populations [7, 8, 36].
These differential effects of EPA versus DHA on LDL-
C levels may be attributable to one or more of at least
three mechanisms. First, DHA (but not EPA) can down-
regulate expression of the LDL receptor and receptor-
mediated clearance of LDL-C by the liver, which is an
important inverse regulator of LDL-C levels. This ap-
pears to occur via a suppression of sterol regulatory
element binding protein (SREBP)-2 expression by DHA
[78, 79]. Second, DHA can upregulate activity of choles-
teryl ester transfer protein (CETP), which promotes core
lipid transfer among lipoproteins, tending to increase
LDL-C and decrease HDL-C levels, while EPA has a
neutral effect on CETP activity [79]. Third, DHA may
exceed EPA in its upregulation of lipoprotein lipase ac-
tivity, which would increase conversion of VLDL to
LDL, thus tending to increase LDL-C [9, 76].
Omega-3 fatty acid dietary supplements
The many non-prescription fish oil products available in
the US are not over-the-counter (OTC) drugs; rather, they
are dietary supplements [80]. This is an important distinc-
tion because dietary supplements are not subject to the
same regulatory oversight and testing as prescription
drugs or OTC drugs [81–84]. They are considered safe
until proven otherwise [83], but are not considered appro-
priate for treatment of disease and thus are not considered
appropriate substitutes for prescription products [80]. Fur-
ther, omega-3 fatty acid dietary supplements tend not only
to have less EPA and DHA per gram than prescription
products, but there are qualitative and potential safety dif-
ferences as well [80]. The amounts of omega-3 fatty acids
actually present in dietary supplements may vary widely
and are usually substantially below the content stated on
the label [73, 85–88]. Of greater potential importance, the
non-omega-3 components of dietary supplement fish oil
products usually include large amounts of saturated fatty
acids [89, 90]. Of greatest significance, most dietary
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supplement omega-3 preparations are oxidized above the
maximum levels recommended by industry standards
[86, 88, 91–94]. A recent study of six leading dietary
supplements (based on sales) examined each for pur-
ity, omega-3 fatty acid levels, and oxidation effects
[94]. Omega-3 fatty acid content varied widely, from
33 to 79%, and the remaining non-omega-3 fat in-
cluded more than 30 different fatty acid species. Fur-
ther, primary and total peroxide levels exceeded
international thresholds. If attempting to reach the
recommended prescription dose of 4 g/day of omega-
3 fatty acids, the approximate 13 capsules (based on
the average 300 mg/capsule) required would lead to intake
of excess calories and high intake of various unwanted
fats, including oxidized fats, potentially negating any
therapeutic benefits [94]. By contrast, Vascepa was found
to be without elevations in lipid oxidation products [94].
Interestingly, oxidation of small dense LDL in vitro was
found to be inhibited by >95% (P <0.001) with non-
oxidized forms of omega-3 fatty acids, but not with a com-
bination of oxidized and non-oxidized omega-3 fatty acids
isolated from dietary supplements and then added to the
in vitro assay [94]. These data suggest a mechanism by
which at least some of the potential benefits of non-
oxidized omega-3 fatty acids (such as prescription
products) may be absent from oxidized preparations
of omega-3 fatty acids (such as dietary supplements).
The human health effects of partially oxidized dietary
supplements are not known, although the levels of
oxidized lipids have been shown to be predictive of
clinical events in patients with CAD [94–96]. In addition
to its direct antioxidant properties, pure EPA has also
been shown to inhibit the oxidation-induced changes in
membrane structural organization such as the formation
of membrane-restricted cholesterol crystalline domains
[5]. Although both EPA and DHA readily intercalate into
the phospholipid bilayers which constitute the outer
membranes of cells, EPA can provide potentially import-
ant in situ antioxidant effects and can stabilize cell mem-
branes in the presence of increasing unesterified
cholesterol content. In contrast, DHA tends to increase
membrane fluidity, reduce overall membrane thickness/
width, and promote cholesterol crystalline domain forma-
tion. These differences suggest that EPA may have net
atheroprotective effects on cell membranes under disease-
like conditions not available with DHA [97].
Plasma EPA levels with EPA treatment
Dietary fish intake raises plasma EPA levels, and there-
fore the Japanese patients in JELIS, with their customary
high fish intake diet, had higher baseline EPA levels than
did patients from Western countries in MARINE and
ANCHOR [36, 98]. Interestingly, treatment with 4 g/day
pure EPA (Vascepa) in MARINE and ANCHOR resulted
in on-treatment EPA levels similar to or higher than the
levels in Japanese patients treated with 1.8 g/day pure
EPA (Epadel) in JELIS (Fig. 3) [98], and comparable to
the higher EPA levels (≥150 μg/mL) associated with a
significantly lower risk of major coronary events in
JELIS versus patients with lower EPA levels (<87 μg/mL;
P = 0.042) [52].
Discussion
JELIS had several strengths, including its large sample size
(N = 18,645) and long follow-up (mean 4.6 years), and the
study showed a statistically significant and clinically sig-
nificant 19% decrease in its primary endpoint of major
coronary events [36]. Several limitations of the study
should be considered, however. Recruitment was based on
the presence of hypercholesterolemia (>250 mg/dL) with
or without CAD, rather than hypertriglyceridemia, which
is the usual indication for omega-3 treatment. JELIS pa-
tients had relatively low baseline TG levels (mean 153 mg/
dL), which may account for the finding of only a very
small (5%) reduction versus placebo in plasma TG levels
with Epadel treatment (although this was highly statisti-
cally significant, P <0.0001) [36]. The finding of a 19% de-
crease in CHD in conjunction with such a small TG
change, and no other significant lipid changes, suggests
that EPA may have cardiovascular effects beyond its lipid/
lipoprotein effects. A recent study of EPA treatment that
examined fatal and nonfatal cardiovascular events 1 year
after percutaneous coronary intervention also demon-
strated cardiovascular benefit but minimal lipid effects
[99]. Patients with acute coronary syndrome (N = 241)
were randomized to pitavastatin alone or pitavastatin plus
EPA. There was an absolute risk reduction of 11% with
EPA treatment (HR, 0.42; 95% CI, 0.21–0.87; P = 0.02)
despite the fact that TG levels remained the same and
were comparable for both groups (P = 0.61) and LDL-C
reduction was comparable for both groups (P = 0.21) dur-
ing the study period [99]. Anti-atherogenic effects of EPA
that may be independent of lipid changes include actions
on key steps in atherogenesis, including inflammation,
thrombosis, and membrane cholesterol metabolism, as
noted above [10].
Another limitation is that the statin doses in JELIS
(pravastatin 10 mg or simvastatin 5 mg) were low, at least
by Western standards. The doses were, however, man-
dated to be up-titrated as needed to achieve LDL-C goals
from Japanese Ministry of Health, Labor, and Welfare
guidelines [36, 44]. Importantly, the modest pravastatin
dose used in JELIS was shown to reduce cardiovascular
disease events (vs control) in the Management of Elevated
Cholesterol in the Primary Prevention Group of Adult
Japanese (MEGA) study [100], which was cited in the
2013 ACC/AHA cholesterol treatment guidelines in
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support of the recommendation for use of statins in an ap-
propriate primary prevention population [32]. Thus, there
is precedent for extrapolating results from a Japanese-only
population to US treatment situations, including lipid
guidelines for reducing cardiovascular risk [32]. Finally,
while JELIS lacked a blinded control group, the blinded
endpoint evaluation (ie, PROBE design) adds some confi-
dence to conclusions based on the study findings. This is
especially true since the “hard endpoints” (such as blindly
adjudicated MI), not likely to be affected by unblinding of
patients and study staff, were reduced to a similar degree
as the primary composite endpoint.
Although robust randomized controlled trial evidence
for decreased cardiovascular disease events from EPA is
based at present on only one large trial (JELIS), there is
now corroboration of this finding from in vitro mechan-
istic studies [13], decreased atherosclerosis endpoints in
two trials [7, 8], and decreased clinical cardiovascular
disease events in a recent additional trial [99]. Further,
two key findings from JELIS subanalyses and substudies
suggest that the REDUCE-IT trial of EPA may also show
cardiovascular disease benefit. First cardiovascular dis-
ease reduction in JELIS was proportional to on-
treatment EPA levels, and the higher dose of EPA in
REDUCE-IT vs JELIS (4 vs 1.8 g/d, respectively) suggests
that REDUCE-IT may show greater cardiovascular dis-
ease reduction. Second, in JELIS, cardiovascular disease
reduction was greater in the subgroup of patients with
higher baseline TG and lower baseline HDL-C levels,
and REDUCE-IT subjects have all been recruited pro-
spectively for and enrolled based on higher baseline TG
levels. Also, the double-blind, placebo-controlled design
of REDUCE-IT may add greater confidence to study
findings compared with JELIS, even though the patient
sample size is less than half.
Conclusions
EPA has several potentially beneficial cardiovascular ef-
fects, including reducing TG levels and other markers or
factors of atherogenesis without raising LDL-C levels, as
does DHA. This is supported by NLA recommendations
which endorse prescription omega-3 fatty acid products
for hypertriglyceridemia but caution that products con-
taining DHA may raise LDL-C, which may interfere with
achievement of LDL-C treatment goals. In addition, puri-
fied EPA, but not DHA, has been demonstrated to have
potentially atheroprotective antioxidant and membrane-
stabilizing effects.
Not only do fish oil omega-3 fatty acid dietary supple-
ments all contain DHA, but as dietary supplements they
Fig. 3 Mean trough total EPA concentrations (±SD) in plasma at baseline and at EOT in Vascepa and Epadel studies [98]. The PK study examined
Vascepa in healthy adult subjects [101]. MARINE evaluated Vascepa in patients with very high TG levels (≥500 and ≤2000 mg/dL) [7]. ANCHOR
evaluated Vascepa in patients with high TG levels (≥200 and <500 mg/dL) despite LDL-C control while on statin therapy [8]. Finally, JELIS evalu-
ated Epadel in Japanese patients with hypercholesterolemia (total cholesterol ≥250 mg/dL) with or without CAD [36]. EOT = 4 weeks for the
phase 1 PK study and 12 weeks in the MARINE and ANCHOR studies. JELIS was an outcome study with a planned follow-up of 5 years. Baseline
values were not subtracted from EOT values. CAD, coronary artery disease; EOT, end of treatment; EPA, eicosapentaenoic acid; JELIS, Japan EPA
Lipid Intervention Study; LDL-C, low-density lipoprotein cholesterol; MARINE, Multi-center, Placebo-controlled, Randomized, Double-blind, 12-week
Study with an Open-label Extension; PK, pharmacokinetic; SD, standard deviation; TG, triglyceride
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are not as highly regulated as prescription or OTC
drugs. Their content of EPA and DHA can be substan-
tially lower than the amounts stated on the product la-
bels. In addition, omega-3 dietary supplements usually
contain significant amounts of saturated fats and oxida-
tion products, which may interfere with their intended
therapeutic benefits. For these reasons, dietary supple-
ments are not intended for the treatment of diseases,
such as hypertriglyceridemia.
Epadel and Vascepa are prescription products contain-
ing highly purified EPA ethyl esters. Epadel reduced car-
diovascular events when added to statins in JELIS, has
been associated with reduced atherosclerotic plaque, and
has a long history of use in Japan with a favorable safety
and tolerability profile. Vascepa is supported by safety
and efficacy data from two prospective phase 3 trials in
patients with either high or very high TG levels, by the
safety profile of several years of post-marketing clinical
use in the US, and by the ongoing collection of safety
and efficacy data over several years in REDUCE-IT. The
effects of Epadel on cardiovascular outcomes in a sec-
ondary prevention population are currently undergoing
confirmation in the RESPECT-EPA trial, while the car-
diovascular disease effects of Vascepa in patients with
persistently high TG levels despite statin use are under
investigation in REDUCE-IT.
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